Light Mode
$1.13 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.13, $0.07 below the day’s high of $1.20
-0.75 (-39.89%) / 6M
Momentum, market sentiment, and recent alerts
GANX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -42.3%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.